Evexta Bio

Evexta Bio (formerly Diaccurate) is a biopharmaceutical company exploring new frontiers in oncology, dedicated to discovering bold, novel therapies with life-saving potential. Currently, this French biotechnology firm is developing two proprietary therapeutic assets with novel mechanisms of action across multiple indications: Rupitasertib (formerly DIACC3010), an optimized S6K inhibitor capable of effectively controlling the AKT1/AKT3 feedback loop. This oral anti-cancer drug has entered clinical trials and is intended for the treatment of refractory ER+ HER2- metastatic breast cancer. The drug is expected to undergo evaluation for efficacy and safety in Phase II/III clinical trials. EVX020 (formerly DIACC2020) is an antibody-drug conjugate program utilizing a unique KIF20A kinesin inhibitor as its payload for the treatment of hematologic malignancies and solid tumors.